New research shows that MenAfriVac® is having a dramatic impact in sub-Saharan Africa
African and European researchers evaluated the effectiveness of the MenAfriVac mass vaccination campaign in Chad in 2011 and found that the vaccine had a dramatic impact on cases of group A meningitis and on carriage of the disease-causing bacteria in the throat.
Approximately 1.8 million children and young adults received a single dose of MenAfriVac in three regions of Chad in December 2011. The incidence of meningitis of any kind in these regions during the 2012 meningitis season was 2.5 per 100,000 people, compared to an incidence of 43.6 per 100,000 in regions where mass vaccination had not been undertaken – a difference of 94%. In addition, no cases of group A meningococcal meningitis were detected in the three vaccinated regions.
Read the London School of Hygiene and Tropical Medicine’s press release of 12 September
View the full article in The Lancet
MenAfriVac® is a registered trademark of Serum Institute of India, Ltd.
PHOTO: A vaccinator prepares to administer the MenAfriVac vaccine during the 2011 mass campaign in Chad.
Photo: Rodrigue Barry/WHO.